OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PROF
Profound Medical Corp.
There isn't enough reported data to score PROF yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PROF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PROF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PROF PE Valuation
PROF has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PROF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PROF's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PROF on earnings quality, reporting a profit while its opponent remains loss making.
PROF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.93 | +$0.42 |
| Q2 2026 | -$0.98 | +$0.49 |
| Q1 2026 | -$1.24 | -$0.01 |
| Q4 2025 | -$1.41 | -$0.28 |
| Q3 2025 | -$1.35 | $0.00 |
| Q2 2025 | -$1.47 | -$0.24 |
| Q1 2025 | -$1.23 | +$0.07 |
| Q4 2024 | -$1.13 | +$0.23 |
PROF is still losing money, but less than at its worst: $0.93 per share over the past year, against $1.53 at its worst in early 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over PROF on profitability, with a higher operating margin.
PROF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +86% |
| Q2 2026 | $2.5M | +12% |
| Q1 2026 | $5.3M | +104% |
| Q4 2025 | $6M | +47% |
| Q3 2025 | $5.3M | +87% |
| Q2 2025 | $2.2M | -1% |
| Q1 2025 | $2.6M | +82% |
| Q4 2024 | $4.1M | +52% |
PROF's revenue has grown year over year for five quarters in a row: $10M last quarter, up 86% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -80% | +89 points |
| Q2 2026 | -446% | +179 points |
| Q1 2026 | -150% | +276 points |
| Q4 2025 | -123% | +77 points |
| Q3 2025 | -169% | +201 points |
| Q2 2025 | -624% | -273 points |
| Q1 2025 | -426% | +121 points |
| Q4 2024 | -200% | +2214 points |
PROF's operating margin was −80% last quarter, up 89 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with PROF at down 33%.
PROF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | +$4.6M |
| Q2 2026 | -$11.3M | +$2.4M |
| Q1 2026 | -$8.6M | -$300K |
| Q3 2025 | -$9.6M | -$2.8M |
| Q2 2025 | -$13.7M | -$7.5M |
| Q1 2025 | -$8.3M | -$3.8M |
| Q4 2024 | -$5.6M | +$1.4M |
| Q3 2024 | -$6.8M | -$2.5M |
PROF has burned cash in almost every quarter: −$35M over the past year, against −$34M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PROF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +205K shares |
| 1 year | +21% | +6.5M shares |
| 3 years | +71% | +15.2M shares |
| 5 years | +79% | +16.1M shares |
| Available history | +826% | +32.6M shares |
PROF has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PROF Net Leverage
PROF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PROF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 57.1 | Neutral |
PROF's weekly RSI is 58 (neutral) and its Stochastic is 57 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PROF PE vs Healthcare Sector
PROF has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PROF on trend strength, trading above more of its moving averages.
PROF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.41 | 16% above |
| 20 week MA | $6.65 | 12% above |
| 50 week MA | $6.77 | 9.9% above |
| 100 week MA | $6.31 | 18% above |
| 200 week MA | $7.97 | 6.6% below |
PROF has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 6.6% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PROF on returns for 2026, with the stronger performance.
PROF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $21.0 | +97% |
| 2021 | $21.0 | $11.7 | -45% |
| 2022 | $11.7 | $10.2 | -13% |
| 2023 | $10.2 | $8.49 | -17% |
| 2024 | $8.49 | $7.15 | -16% |
| 2025 | $7.15 | $7.37 | +3.1% |
| 2026 YTD | $7.37 | $7.44 | +0.9% |
PROF has finished lower in four of the last six years. It's up 0.9% so far in 2026.